Search
for
Sort by
Research 14
- Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
- Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
- Sacituzumab Govitecan-Hziy (Trodelvy™)
- Clinical perspective on management of key adverse events with sacituzumab govitecan
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
- Antibody-drug conjugate induced hair loss responds to minoxidil: A case report
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Real-world pharmacovigilance insights into drug-induced risk of alopecia
- Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling
- Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- Cancer-Related Alopecia Risk and Treatment
- Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases